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Prolonged excretion of Poliovirus 
among individuals with Primary 
immunodeficiency Disorder: an 
analysis of the World health 
Organization registry
Grace Macklin1*, Yi Liao1,2, Marina Takane1, Kathleen Dooling1, Stuart Gilmour 2,  
Ondrej Mach1, Olen M. Kew3,4, Roland W. Sutter1 and The iVDPV Working Group
1 World Health Organization, Geneva, Switzerland, 2 University of Tokyo, Tokyo, Japan, 3 Centers for Disease Control and 
Prevention, Atlanta, GA, United States, 4 Taskforce for Child Health, Atlanta, GA, United States
Individuals with primary immunodeficiency disorder may excrete poliovirus for extended 
periods and will constitute the only remaining reservoir of virus after eradication and 
withdrawal of oral poliovirus vaccine. Here, we analyzed the epidemiology of prolonged 
and chronic immunodeficiency-related vaccine-derived poliovirus cases in a registry 
maintained by the World Health Organization, to identify risk factors and determine the 
length of excretion. Between 1962 and 2016, there were 101 cases, with 94/101 (93%) 
prolonged excretors and 7/101 (7%) chronic excretors. We documented an increase in 
incidence in recent decades, with a shift toward middle-income countries, and a predom-
inance of poliovirus type 2 in 73/101 (72%) cases. The median length of excretion was 
1.3 years (95% confidence interval: 1.0, 1.4) and 90% of individuals stopped excreting 
after 3.7 years. Common variable immunodeficiency syndrome and residence in high-in-
come countries were risk factors for long-term excretion. The changing epidemiology of 
cases, manifested by the greater incidence in recent decades and a shift to from high- to 
middle-income countries, highlights the expanding risk of poliovirus transmission after 
oral poliovirus vaccine cessation. To better quantify and reduce this risk, more sensitive 
surveillance and effective antiviral therapies are needed.
Keywords: polio eradication, primary immunodeficiency, vaccine-derived poliovirus, oral poliovirus vaccine, 
immunodeficiency-related vaccine-derived poliovirus
inTrODUcTiOn
Since the launch of the Global Polio Eradication Initiative in 1988, there has been substantial progress 
toward eradication, documented by a decline in the incidence of cases from >350,000 in 1988 to 37 in 
2016, and a decrease in the number of endemic countries from 125 to 3 (1). Although wild poliovirus 
type 1 continues to circulate in Afghanistan, Nigeria, and Pakistan, no wild poliovirus type 2 or wild 
poliovirus type 3 have been detected globally since October 1999 (2) and November 2012 (3), periods 
of 17 and 4 years, respectively.
Abbreviations: AFP, acute flaccid paralysis; CVID, common variable immunodeficiency; iVDPV, immunodeficiency-related 
vaccine-derived poliovirus; OPV, oral poliovirus vaccines; PID, primary immunodeficiency disorder; VDPV, vaccine-derived 
poliovirus; WHO, World Health Organization.
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These achievements have been accomplished through the 
extensive use of oral poliovirus vaccines (OPV), which are easy to 
administer, suitable for mass campaigns, and able to induce both 
humoral and mucosal immunity (4). However, in rare instances, 
live Sabin strains contained in OPV can cause vaccine-associated 
paralytic poliomyelitis, with paralytic manifestations indistin-
guishable from those caused by wild poliovirus (4). Furthermore, 
these viruses have the potential to revert to neurovirulence and 
re-acquire the transmissibility characteristics of wild poliovirus, 
resulting in outbreaks of circulating vaccine-derived poliovirus 
(VDPV) (5). In the presence of high population immunity, 
VDPVs rarely emerge and cause outbreaks. However, in areas 
with low population immunity, these viruses could potentially 
re-establish endemic transmission (6).
Immunodeficiency-related vaccine-derived poliovirus 
(iVDPV) is a type of VDPV in which individuals with a primary 
immunodeficiency disorder (PID) excrete Sabin polioviruses; in 
some cases, for substantially longer periods than immunocompe-
tent individuals (4). After exposure to OPV, immunocompetent 
individuals usually excrete the vaccine virus for 4–8  weeks (7). 
However, in immunodeficient individuals, an inability to mount an 
adequate immune response can result in persistence of the intesti-
nal infection with poliovirus and prolonged viral shedding (8). In 
the process, the virus can mutate to re-acquire the neurovirulence 
and transmissibility characteristics of wild poliovirus (9–12).
To address the risks associated with OPV use, the Strategic Plan 
of Action 2013–2018 of the Global Polio Eradication Initiative 
calls for a sequential global withdrawal of OPV, starting with the 
Sabin type 2 component that was removed in April 2016 and fol-
lowed by Sabin type 1 and Sabin type 3 after certification of wild 
type 1 and 3 eradication, respectively (13). Although this strategy 
may minimize the long-term risk of circulating VDPV outbreaks, 
iVDPV cases will remain a potential source of live poliovirus 
in communities after the withdrawal of OPV and in the post 
eradication era, and could pose a substantial risk of poliovirus 
reintroduction in the population. The post-OPV cessation risks 
of long-term excretors have been modeled previously (14–16).
A number of case reports and case series of iVDPV excretors 
have been published with a systematic review of published cases 
undertaken (17), and more recently, studies have assessed iVDPV 
excretion among persons with PIDs (18–20). However, many of 
these works focus on only a subset of iVDPV cases, with case 
reports often limited to upper-middle income and high-income 
countries and patients with paralysis.
We present analysis of iVDPV cases known to the World 
Health Organization (WHO), from the inception of widespread 
OPV use (1962–2016). The main objectives of this study are 
to conduct demographic, risk factor, and survival analysis of 
reported iVDPV cases to determine the populations most at risk 
and to better understand the threat posed by iVDPV cases to 
global poliovirus eradication.
MaTerials anD MeThODs
study Population
This study analyzed cases in the iVDPV case registry main-
tained by WHO, containing reported cases from 1962 to 2016, 
irrespective of reporting source or paralysis status (see Table S2 
in Supplementary Table). The main sources contributing cases to 
the registry include: (1) the acute flaccid paralysis (AFP) surveil-
lance system, which is the routine way countries report cases; (2) 
the regional polio laboratory network; (3) specific studies and 
pilot poliovirus surveillance projects targeting PID patients; and 
(4) regularly conducted systematic literature reviews of scientific 
journals reporting on iVDPV cases, where key search terms 
include VDPV, iVDPV, immunodeficiency, immunocomprised, 
excretion, polio, and “vaccine-associated paralytic poliomyelitis.” 
In order to obtain the most recent information on ongoing cases, 
corresponding authors of case reports and/or relevant scientific 
and medical personnel, including regional laboratory coordina-
tors, were contacted.
Inclusion criteria comprised: excretion of poliovirus for greater 
than 6 months; confirmed PID; and laboratory-confirmed VDPV. 
A prolonged excretor was defined as a person excreting virus for 
≥6 months and ≤5 years, and a chronic excretor was defined as 
excreting for >5 years (14).
Primary immunodeficiency disorder in the registry includes 
individuals with congenital onset of B-cell deficiency, T-cell 
deficiency, major histocompatibility complex deficiency, or a 
combination of the above. For the purposes of these analyses, 
immunodeficiency disorders were divided into the following 
broad categories:
•	 Antibody disorder, including hypogammaglobulinemia, 
agammaglobulinemia, X-linked agammaglobulinemia, and 
other antibody deficiencies.
•	 Severe combined immunodeficiency disorder and other com-
bined humoral/T-cell deficiencies.
•	 Common variable immunodeficiency disorder (CVID).
•	 Other, including major histocompatibility complex deficien-
cies, the immunodeficiency, centromere instability, and facial 
anomalies syndrome, as well as other unknown or undiag-
nosed causes of immunodeficiency.
laboratory Processing of Poliovirus 
isolates
Until the establishment of sensitive surveillance for polio eradica-
tion, viruses were mainly isolated in a few specialized laborato-
ries. With implementation of surveillance for polio eradication, 
poliovirus was increasingly isolated from patient stool samples by 
laboratories participating in the WHO Global Polio Laboratory 
Network. Isolates were identified by several steps: first, specimens 
were grown in tissue culture; second, molecular methods were 
used to identify the serotype; and third, intratypic differentiation 
to determine vaccine or wild strains was done either by enzyme-
linked immunosorbent assay using highly specific cross-absorbed 
antisera and/or by diagnostic reverse transcriptase-polymerase 
chain reaction (21). If the enzyme-linked immunosorbent 
assay and molecular intratypic differentiation methods yielded 
discordant results, the ~900-nucleotide interval encoding the 
major capsid protein, the viral protein 1 (VP1), was sequenced. 
Poliovirus genomes appear to evolve at a rate of ~1.1% mutations 
in VP1 region per year (22) and VDPVs are defined as having 
a VP1 nucleotide divergence >1% for type 1 and 3, and >0.6% 
FigUre 1 | Year of detection of 101 reported chronic and prolonged 
immunodeficiency-related vaccine-derived poliovirus cases from 1962 to 
2016, by income classification of country of residence: low income (n = 1), 
lower-middle income (n = 24), upper-middle income (n = 47), and 
high-income (n = 29). Income classification based on 2016 World Bank 
Classification.
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for type 2, from the corresponding parenteral OPV strain (23), 
consistent with prolonged replication or transmission.
Demographic and clinical Variables
Cases were recorded with the following demographic and clinical 
parameters: year of detection; country of residence and its income 
classification [based on the 2016 World Bank classifications (24)]; 
date of birth; date of onset; age at onset; gender; PID; presence or 
absence of paralysis; OPV vaccination history; clinical outcome 
(alive, alive and stopped excreting, dead or unknown); and first 
and most recent positive specimen dates, serotype of virus, 
percentage VP1 divergence from the parenteral Sabin strain, and 
recombination with other non-polio enteroviruses.
statistical analysis
Descriptive analysis was conducted to identify demographic and 
clinical characteristics of iVDPV cases. According to available 
information, duration of excretion was estimated following the 
algorithm provided in Table S1 in Supplementary Material. 
The algorithm bases the length of excretion on either the time 
period between OPV administration (or exposure) and the last 
iVDPV isolate, the time period calculated by VP1 divergence 
from parental Sabin strain based on an evolution rate of ~1.1% 
divergence per year (22), or where this information was not avail-
able, the excretion time under observation. To model the length 
of excretion, Kaplan–Meier survival analysis was employed and 
log-rank tests used to determine difference in survival times 
between groups. To allow for multiple comparisons, the P-value 
for significance was set at P < 0.01. All analyses were conducted 
using the statistical software R 3.3.1 (25) and Stata MP 13 (26).
resUlTs
Demographics
As of July 2016, the WHO registry included 110 suspected iVDPV 
cases with onset of excretion or paralytic symptoms during 
1962–2016. Of these, 101 (91.8%) met the definition of prolonged 
or chronic iVDPV excretion and were included in the analysis. 
Figure 1 shows the number of reported iVDPV cases over time 
since 1962. There has been an increase in the number of reported 
cases since the year 2000, with the highest number the period 
since 2010 (56/101). Within this, there are two divergent trends: 
an increase in cases reported from low- and middle-income 
countries and a decrease in the number of cases reported from 
high-income countries (Figure 1).
Figure  2 provides the geographic location of these cases by 
associated serotype, illustrating a large concentration of cases 
around the Middle East. The characteristics of the 101 prolonged 
and chronic iVDPV cases are presented in Table 1. The residence 
of cases by worldwide region shows the highest proportion of 
cases 43/101 (43%) occurred in the Eastern Mediterranean 
Region. There were 24/101 (24%) cases in lower-middle-income 
countries, 47/101 (47%) in upper-middle income countries, and 
29/101 (29%) in high-income countries, with all seven chronic 
excretor cases resident in high-income countries. Only one 
case was reported from a low-income country, which was in 
Afghanistan in 2013.
Out of the 101 cases, 63/98 (64%) were males, 71/100 (71%) 
presented with paralytic manifestations, as defined by AFP, and 
the most common age of onset was <1 year in 46/100 (46%) cases, 
followed by 1 to <5 years old in 37/100 (37%) (Table 1).
Underlying PiD
The underlying immunodeficiency disorders of cases are 
shown in Table 1. Antibody disorders were the most frequent, 
accounting for 31/91 (34%) of the cases, primarily composed of 
hypogammaglobulinemia, agammaglobulinemia, and X-linked 
agammaglobulinemia. Severe combined immunodeficiency dis-
order and CVID were also common, present in 25/92 (27%) and 
21/92 (23%) of cases, respectively. All the seven chronic excretors 
had CVID.
Virological Factors
The serotype of excreted virus was predominantly type 2 polio-
virus, in 68/101 cases (67%), followed by type 1 in 15/101 cases 
(15%) and type 3 in 13/101 cases (13%) (Table 1). Among the 
six cases with multi-serotype infections, two were type 1 and 2 
co-infections and three were type 2 and 3 co-infections, result-
ing in 73/101 (72%) cases in the database associated with type 2 
poliovirus.
survival analysis
The length of excretion was calculated for all 101 iVDPV 
cases, of which 94 (93%) were prolonged excretors and 7 (7%) 
were chronic excretors. At the time of analysis, 48/101 (48%) 
individuals had died and 36/101 (36%) had stopped excreting. 
There were 8/101 (8%) individuals who were still alive and 
excreting at last specimen and 9/101 (9%) were lost to follow-
up (Table 1).
FigUre 2 | Geographic location of 101 reported chronic and prolonged immunodeficiency-related vaccine-derived poliovirus cases, 1962–2016. Shown by 
serotype of virus in most recent specimen available: 1 (n = 15), 2 (n = 68), 3 (n = 13), 1 + 2 (n = 2), and 2 + 3 (n = 3).
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The median length of excretion for all 101 cases was 1.3 years 
[95% confidence interval (CI): 1.0–1.4], with a range of 0.5–
28.6 years. Figure 3 shows the Kaplan–Meier survival curves for 
time to cessation of poliovirus excretion, stratified by PID and 
country income classification. After 2.4 and 3.7 years, 80 and 90% 
of individuals had stopped excreting, respectively (Figure 3A). 
There was a significant difference in the Kaplan–Meier curves 
for length of excretion between different PIDs (P < 0.001), with 
individuals with CVID having the longest length of excretion, 
a median of 3.0 years (95% CI: 1.6–6.7) (Figure 3B). There was 
also a highly significant difference between different income 
classification of countries (P <  0.001), with a longer median 
length of excretion for high-income countries (2.5  years, 95% 
CI: 1.3–3.7) than upper-middle income countries (1.0 year, 95% 
CI: 0.9–1.3), lower-middle income countries (1.0 years, 95% CI: 
0.8–1.5), and low-income countries (0.8 years) (Figure 3C). No 
statistical significance was found in the Kaplan–Meier curves 
for sex (P = 0.68) or poliovirus serotype (P = 0.21) (results not 
shown).
evolution of length of excretion
To understand the risk of iVDPV2 to the communities, we 
stratified the length of excretion by the date of onset (Table 2). 
Only those cases that were known to have stopped excreting 
(outcome alive and stopped excreting or dead) were included in 
this analysis to ensure comparability of the length of excretion 
between the two time periods 1962–2010 and 2011–2016. There 
was a decrease in the median length of excretion from cases with 
onset in 1962–2010 to 2011–2016: 1.75 years (95% CI: 1.3–2.5) 
and 1.0 years (95% CI: 0.8–1.4), respectively. The difference in 
length of excretion for the two time periods was found to be 
highly statistically significant when all serotypes (P < 0.001) were 
considered and specifically for type 2 (P < 0.001).
DiscUssiOn
Our analyses document the changing epidemiology of iVDPV 
cases since the turn of the millenium, when the incidence of 
reported cases dramatically increased. The cases reside primar-
ily from middle-income countries and are concentrated in the 
Middle East and North Africa. We confirm that the preponder-
ance of cases are excreting poliovirus type 2, and demonstrate 
that the length of virus excretion has decreased in recent years. 
We also estimated that the last reported chronic excretor (greater 
than 5 years of excretion) had onset in 1998 and, finally, identified 
CVID as the major risk factor for chronic excretion.
The documented increase in number of reported iVDPV cases 
since the year 2000 was consistent with previous reports (17) and 
could be attributed to better case ascertainment, improved health 
care allowing immunodeficient patients to survive longer, or a 
combination of these factors. The surveillance sensitivity for AFP 
has risen in parallel with case incidence since 2000; however, this 
system is designed to capture cases with paralytic manifestations 
only (28), including those with PID. During the same period, 
capabilities of PID diagnostics have been enhanced and may 
now be available in many low- and middle-income countries. 
Therefore, it is possible that the increase in iVDPV cases is a 
surveillance artifact.
The shift in iVDPV cases from high-income to middle-income 
countries likely reflects two different trends: (1) high-income 
countries have changed their immunization schedules and 
switched to exclusive inactivated poliovirus vaccine use (thus 
Table 1 | Baseline characteristics of 101 reported chronic and prolonged immunodeficiency-related vaccine-derived poliovirus cases at time of detection, 1962–2016.
characteristic number of cases, n/N (%) Prolonged excretor casesa, n/N (%) chronic excretor casesb, n/N (%)
Total 101 94 7
gender
Male 63/98 (64) 59/91 (65) 4/7 (57)
Female 35/98 (36) 32/91 (35) 3/7 (43)
age at onset or first positive specimen
<1 year 46/100 (46) 46/93 (49) 0/7 (0)
1 to <5 years 37/100 (37) 37/93 (40) 0/7 (0)
5 to <10 years 7/100 (7) 6/93 (6) 1/7 (14)
10 to <20 years 5/100 (5) 2/93 (2) 3/7 (43)
20 to <30 years 3/100 (3) 1/93 (1) 2/7 (29)
≥30 years 2/100 (2) 1/93 (1) 1/7 (14)
Paralysis
Yes 71/100 (71) 67/93 (72) 4/7 (57)
No 29/100 (29) 26/93 (28) 3/7 (43)
country of residence income classificationc
High income 29/101 (29) 22/94 (23) 7/7 (100)
Upper-middle income 47/101 (47) 47/94 (50) 0/7 (0)
Lower-middle income 24/101 (24) 24/94 (26) 0/7 (0)
Low income 1/101 (1) 1/94 (1) 0/7 (0)
WhO region of residence
Eastern Mediterranean Region 43/101 (43) 43/94 (46) 0/7 (0)
African Region 6/101 (6) 6/94(6) 0/7 (0)
Western Pacific Region 10/101 (10) 7/94 (7) 3/7 (43)
European Region 14/101 (14) 10/94 (11) 4/7 (57)
South-East Asian Region 13/101 (13) 13/94 (14) 0/7 (0)
Region of the Americas 15/101 (15) 15/94 (16) 0/7 (0)
immunodeficiency disorder
SCID and other combined humoral/T-cell deficiencies 27/92 (29) 27/85 (32) 0/7 (0)
SCID 25/92 (27) 25/85 (29) 0/7 (0)
CVID 21/92 (23) 14/85 (16) 7/7 (100)
Antibody disorders 31/92 (33.7) 31/85 (36) 0/7 (0)
HGG 10/92 (11) 10/85 (12) 0/7 (0)
XLA 12/92 (13) 12/85 (14) 0/7 (0)
AGG 5/92 (5) 5/85 (6) 0/7 (0)
Other disorders 13/92 (14) 13/85 (15) 0/7 (0)
MHC II 6/92 (7) 6/85 (7) 0/7 (0)
HLA-DR 4/92 (4) 4/85 (5) 0/7 (0)
serotyped
1 15/101 (15) 12/94 (13) 3/7 (43)
2 68/101 (67) 64/94 (68) 4/7 (57)
3 13/101 (13) 13/94 (14) 0/7 (0)
1 + 2 2/101 (2) 2/94 (2) 0/7 (0)
2 + 3 3/101 (3) 3/94 (3) 0/7 (0)
All type 2 associated 73/101 (72) 69/94 (73) 4/7 (57)
Outcome status
Dead 48/101 (48) 45/94 (48) 3/7 (43)
Stopped excreting 36/101 (36) 34/94 (36) 2/7 (29)
Alive (and excreting at last specimen) 8/101 (8) 7/94 (7) 1/7 (14)e
Unknown 9/101 (9) 8/94 (9) 1/7 (14)
AGG, agammaglobulinemia; CVID, common variable immunodeficiency disorder; HGG, hypogammaglobulinemia; HLA-DR, human leukocyte antigen-antigen D related; MHC II; 
major histocompatibility complex type II; SCID, severe combined immunodeficiency disorder; WHO, World Health Organization; XLA, X-linked agammaglobulinemia.
aDefined as excreting virus for ≥6 months and ≤5 years.
bDefined as excreting for >5 years.
cBased on 2016 World Bank Classification.
dSerotype of virus in most recent specimen available.
eThis case has been published (27).
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Table 2 | Kaplan–Meier Estimates of the length of excretion for 84 prolonged and chronic immunodeficiency-related vaccine-derived poliovirus cases with outcome 
dead or stopped excreting, stratified by date of onset, 1962–2016.
serotypea Total number of 
cases
Date of onset 1962–2010 Date of onset 2011–2016 P-valuec
number of cases Median length of 
excretion, years
95% ci number of cases Median length of 
excretion, years
95% ci
1 13 9 3.20b 4 0.96b 0.002
2 54 27 1.50 1.1, 2.3 27 0.82 0.8, 1.0 <0.001
3 12 3 1.25b 9 1.30b 0.24
All 84 41 1.75 1.3, 2.5 43 1.00 0.8, 1.4 <0.001
CI, confidence interval.
aSerotype of most recent specimen available.
bNo upper CI.
cP-value for log-rank test for difference in Kaplan–Meier survival curves; tests of significance were two-sided.
FigUre 3 | Kaplan–Meier curves for the length of poliovirus excretion in reported chronic and prolonged immunodeficiency-related vaccine-derived poliovirus 
cases, 1962–2016. (a) For all reported cases (n = 101, dotted lines: 95% Confidence Limits). (b) Comparison by income classification of country of residence: low 
income (n = 1), lower-middle income (n = 24), upper-middle income (n = 47), and high-income (n = 29). Two-tailed P < 0.001 for log-rank test for equality of 
Kaplan–Meier curves. (c) Comparison by primary immunodeficiency disorder: antibody disorders (n = 31), CVID (n = 21), SCID and other combined humoral T-cell 
deficiencies (n = 27), and other disorders (n = 13). Two-tailed P < 0.001 for log-rank test for equality of Kaplan–Meier curves. Abbreviation: CVID, common variable 
immunodeficiency disorder; SCID, severe combined immunodeficiency disorder.
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preventing new iVDPVs from being generated); (2) middle-
income countries have established increasingly sensitive surveil-
lance for AFP, which better captures PIDs with paralysis; and 
(3) health systems in middle-income countries provide better 
medical care for PIDs, allowing these cases to be diagnosed and 
treated. However, this shift in case distribution causes new chal-
lenges to polio eradication.
The striking concentration of iVDPV cases in the Middle East 
and North Africa may be due to: (1) an increased risk of PID due 
to co-sanguinity (29) and (2) an interest of immunologists in these 
Regions to strengthen surveillance for PID and create immunode-
ficiency registries. In particular, iVDPV surveillance projects have 
taken place in Egypt (30), Iran (31), and Tunisia (20).
Our analysis is consistent with previous studies documenting 
that iVDPV type 2 constitutes more than 70% of all iVDPV cases 
(17), including a case that has excreted poliovirus type 2 for almost 
30  years (27). Since the removal of Sabin type 2 from OPV was 
implemented in April 2016, no further Sabin type 2 are being intro-
duced into populations, except for outbreak control (13, 32), which 
should prevent the generation of almost all new iVDPV type 2 cases.
On average, the duration of excretion of poliovirus among 
iVDPV cases is relatively short (approximately 1 year) and has 
further declined in recent years. This declining length of polio-
virus excretion for all serotypes, but especially type 2, is likely to 
be associated with the shift in cases from high to middle income 
countries. This may be caused by shorter survival of iVDPV cases 
in middle-income countries or a higher likelihood of spontane-
ous cessation of excretion. However, we have little evidence to 
support the latter assumption.
We also document that chronic excretors are all associated 
with CVID in our case series. This is not surprising since CVID 
consists of a variety of underlying pathologies associated with 
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later diagnosis and longer survival than some of the other PIDs 
diagnoses (15, 33). What is more surprising is that all chronic 
excretors originated from high-income countries, and that no 
new chronic cases have been detected since 2009. Whether this 
is a reflection of the quality of the health systems in developing 
countries to both detect and care for PID patients remains an 
open question.
In our case series, only eight iVDPV cases were documented 
to be alive and excreting. The rest either had a fatal outcome or 
spontaneously stopped excretion. An additional nine cases were 
lost to follow-up or had no information on excretion. However, if 
we apply the observed mortality to these cases, very few would be 
expected to be alive and excreting. Therefore, the known preva-
lence of actively excreting iVDPV cases (i.e., those captured by 
current surveillance systems) is small.
In terms of limitations, our analyses could only focus on those 
iVDPV cases reflected in the WHO registry. Our study does not 
address the unknown number of PIDs who excrete poliovirus 
but have not been captured by the AFP surveillance system 
because they are not paralyzed and did not come to the atten-
tion of immunologists because of either a lack of suspicion or 
specialist immunological services are not available. This reflects 
the broader challenge of tracking iVDPV cases and limitations 
of registries in the absence of routine screening of PID patients 
for poliovirus infection and excretion. Furthermore, the informa-
tion available in the registry is limited by the quality of reported 
data. In the calculation for length of excretion, cases that were 
still excreting or lost to follow-up were censored at the time of 
last positive sample and may continue to excrete for longer time 
periods. Furthermore, the analysis assumed a standard evolution 
rate of 1.1% mutations in VP1 region of the poliovirus genome 
per year.
Our results have important implications for the polio end-
game. The withdrawal of Sabin type 2 poliovirus in April 2016 
went well (32), and future immunity to type 2 poliovirus will be 
induced solely by inactivated poliovirus vaccine. Our duration of 
excretion analysis suggests that the highest risk period for iVDPV 
cases re-seeding communities is in the next 2–3 years.
However, there are ways in which the Global Polio Eradication 
Initiative can actively decrease the risk of iVDPV cases. Generating 
effective therapeutic options for clearing poliovirus infections is 
critical. Progress has been made in this field over the last decade 
or more, and antiviral drugs are nearing practical applicability 
(34). The first drug, a capsid inhibitor, is now ready for deploy-
ment under an Investigational New Drug protocol (35). Because 
of high levels of drug resistance, a second drug is needed for a 
combination treatment (35) and related studies with a protease 
inhibitor are in progress (36). These drugs, as well as specific 
high-titer monoclonal antibodies, should provide effective treat-
ment for iVDPV excretors. In this context, identifying PIDs with 
poliovirus to enable treatment with these new drugs becomes an 
urgent priority, not only for public health but also because these 
patients are at risk of developing paralytic poliomyelitis, which 
has a high mortality burden.
In parallel, we need to establish sensitive surveillance systems 
to identify and report iVDPV cases with or without paralytic 
symptoms, which constitute the last remaining sources of 
poliovirus type 2. Recent modeling by Tebbens et al. has shown 
that treating iVDPVs with antiviral drugs alone will have limited 
impact and requires integration with expanded surveillance 
(15). This surveillance system would be complementary to the 
AFP surveillance system that captures children with paralytic 
manifestations. The new system would also target children with 
PIDs (without paralytic manifestations) and would use the 10 
Warning Signs of the Jeffrey Modell Foundation as a screening 
case definition (37). Children meeting at least two signs would 
then be included in the AFP surveillance system and followed up 
accordingly (with two stool samples collected and related labora-
tory investigations). The Strategic Advisory Group of Experts on 
Immunization Polio Working Group has endorsed this approach, 
and pilot country studies are being established (38). Furthermore, 
analysis suggests that extended surveillance could save between 
US$0.7 to 1.5 billion and identify 25–90% of asymptomatic 
iVDPV excretors (16).
This dual approach of developing therapeutic options to clear 
poliovirus infection and establishing sensitive surveillance for 
PIDs should further quantify the risks and would allow the Global 
Polio Eradication Initiative to actively mitigate these risks, so that 
global polio eradication cannot be undone by few iVDPV cases 
that may inadvertently re-seed communities with poliovirus, 
potentially leading to re-establishment of endemic or epidemic 
transmission. With these enhancements to the surveillance and 
treatment system for PIDs, we can make the final steps to a world 
free of polio.
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